Techno Trends
Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).
Terns Pharmaceuticals Secures FDA Breakthrough Therapy Designation for TERN-701 in CML
Terns Pharmaceuticals, Inc. has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for TERN-701, a novel oral allosteric BCR::ABL1 inhibitor....
FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer
FORE Biotherapeutics has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug plixorafenib, developed for the treatment of adult patients with BRAF V600E-mutated high-grade glioma, a severe form of brain cancer....
Sanofi Secures FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease
The US Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to venglustat, an investigational oral therapy, for the treatment of neurological symptoms in type 3 Gaucher disease (GD3)....
Cleveland Clinic and Kent State Team Use Quantum Computing to Advance Drug Design
Researchers at the Cleveland Clinic, in collaboration with PhD students from Kent State University, have developed a quantum computing-based method that significantly improves drug design...
Shield Therapeutics Receives FDA Approval for ACCRUFeR® in Pediatric Patients
Shield Therapeutics plc has announced that the U.S. Food and Drug Administration (FDA) has approved ACCRUFeR® (ferric maltol) for the treatment of iron deficiency in children aged 10 years and older....
Case Western Reserve Scientists Discover Novel Molecular Target for Parkinson’s Disease
Researchers at Case Western Reserve University have discovered a new biochemical pathway that could lead to treatments targeting the underlying causes of Parkinson’s disease....
Sanofi Received Breakthrough Therapy and Orphan Drug Designations for Rilzabrutinib
Sanofi has announced that Rilzabrutinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of warm autoimmune hemolytic anemia (wAIHA)....
Immix Biopharma’s NXC-201 Secures FDA Breakthrough Therapy Status for AL Amyloidosis
Immix Biopharma, Inc. has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its investigational therapy, NXC-201, aimed at treating relapsed or refractory AL amyloidosis....
Ipsen’s IPN60340 receives FDA Breakthrough Therapy Designation for first-line unfit AML
Ipsen has announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) to IPN60340 in combination with venetoclax and azacitidine...
Protara Therapeutics Secures FDA Breakthrough Therapy Designation for TARA-002 in Pediatric Lymphatic Malformations
Protara Therapeutics, Inc., has received both Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA) for TARA-002....
